UNLABELLED: The role of interleukin-6 (IL-6) in autoimmunity attracts attention because of the clinical usage of monoclonal antibodies to IL-6 receptor (IL-6R), designed to block IL-6 pathways. In autoimmune liver disease, activation of the hepatocyte IL-6/STAT3 (signal transducer and activator of transcription 3) pathway is associated with modulating pathology in acute liver failure, in liver regeneration, and in the murine model of concanavalin A-induced liver inflammation. We have reported that mice expressing a dominant negative form of transforming growth factor beta receptor II (dnTGFbetaRII) under control of the CD4 promoter develop both colitis and autoimmune cholangitis with elevated serum levels of IL-6. Based on this observation, we generated IL-6-deficient mice on a dnTGF-betaRII background (dnTGFbetaRII IL-6(-/-)) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histopathology, and immunohistochemistry of liver and colon tissues. As expected, based on reports of the use of anti-IL-6R in inflammatory bowel disease, dnTGFbetaRII IL-6(-/-) mice manifest a dramatic improvement in their inflammatory bowel disease, including reduced diarrhea and significant reduction in intestinal lymphocytic infiltrates. Importantly, however, autoimmune cholangitis in dnTGFbetaRII IL-6(-/-) mice was significantly exacerbated, including elevated inflammatory cytokines, increased numbers of activated T cells, and worsening hepatic pathology. CONCLUSION: The data from these observations emphasize that there are distinct mechanisms involved in inducing pathology in inflammatory bowel disease compared to autoimmune cholangitis. These data also suggest that patients with inflammatory bowel disease may not be the best candidates for treatment with anti-IL-6R if they have accompanying autoimmune liver disease and emphasize caution for therapeutic use of anti-IL-6R antibody.
UNLABELLED: The role of interleukin-6 (IL-6) in autoimmunity attracts attention because of the clinical usage of monoclonal antibodies to IL-6 receptor (IL-6R), designed to block IL-6 pathways. In autoimmune liver disease, activation of the hepatocyte IL-6/STAT3 (signal transducer and activator of transcription 3) pathway is associated with modulating pathology in acute liver failure, in liver regeneration, and in the murine model of concanavalin A-induced liver inflammation. We have reported that mice expressing a dominant negative form of transforming growth factor beta receptor II (dnTGFbetaRII) under control of the CD4 promoter develop both colitis and autoimmune cholangitis with elevated serum levels of IL-6. Based on this observation, we generated IL-6-deficient mice on a dnTGF-betaRII background (dnTGFbetaRIIIL-6(-/-)) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histopathology, and immunohistochemistry of liver and colon tissues. As expected, based on reports of the use of anti-IL-6R in inflammatory bowel disease, dnTGFbetaRIIIL-6(-/-) mice manifest a dramatic improvement in their inflammatory bowel disease, including reduced diarrhea and significant reduction in intestinal lymphocytic infiltrates. Importantly, however, autoimmune cholangitis in dnTGFbetaRIIIL-6(-/-) mice was significantly exacerbated, including elevated inflammatory cytokines, increased numbers of activated T cells, and worsening hepatic pathology. CONCLUSION: The data from these observations emphasize that there are distinct mechanisms involved in inducing pathology in inflammatory bowel disease compared to autoimmune cholangitis. These data also suggest that patients with inflammatory bowel disease may not be the best candidates for treatment with anti-IL-6R if they have accompanying autoimmune liver disease and emphasize caution for therapeutic use of anti-IL-6R antibody.
Authors: T Nagano; K Yamamoto; S Matsumoto; R Okamoto; M Tagashira; N Ibuki; S Matsumura; K Yabushita; N Okano; T Tsuji Journal: J Clin Immunol Date: 1999-11 Impact factor: 8.317
Authors: R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: V Barak; C Selmi; M Schlesinger; M Blank; N Agmon-Levin; I Kalickman; M E Gershwin; Y Shoenfeld Journal: J Autoimmun Date: 2009-10-28 Impact factor: 7.094
Authors: T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu Journal: Nature Date: 1986 Nov 6-12 Impact factor: 49.962
Authors: Yugo Ando; Guo-Xiang Yang; Masanobu Tsuda; Kazuhito Kawata; Weici Zhang; Takahiko Nakajima; Koichi Tsuneyama; Patrick Leung; Zhe-Xiong Lian; Kazuichi Okazaki; William M Ridgway; Gary L Norman; Aftab A Ansari; Xiao-Song He; Ross L Coppel; M Eric Gershwin Journal: Hepatology Date: 2012-10 Impact factor: 17.425
Authors: Jijing Tian; Guoxiang Yang; Huan-Yuan Chen; Daniel K Hsu; Alexey Tomilov; Kristin A Olson; Ali Dehnad; Sarah R Fish; Gino Cortopassi; Bin Zhao; Fu-Tong Liu; M Eric Gershwin; Natalie J Török; Joy X Jiang Journal: FASEB J Date: 2016-09-14 Impact factor: 5.191
Authors: Amy Dhirapong; Guo-Xiang Yang; Steven Nadler; Weici Zhang; Koichi Tsuneyama; Patrick Leung; Stuart Knechtle; Aftab A Ansari; Ross L Coppel; Fu-Tong Liu; Xiao-Song He; M Eric Gershwin Journal: Hepatology Date: 2013-02 Impact factor: 17.425
Authors: Yugo Ando; Guo-Xiang Yang; Thomas P Kenny; Kazuhito Kawata; Weici Zhang; Wenting Huang; Patrick S C Leung; Zhe-Xiong Lian; Kazuichi Okazaki; Aftab A Ansari; Xiao-Song He; Pietro Invernizzi; William M Ridgway; Qianjin Lu; M Eric Gershwin Journal: J Autoimmun Date: 2013-02-08 Impact factor: 7.094